journal article·2018-04

Multifunctional Shell–Core Nanoparticles for Treatment of Multidrug Resistance Hepatocellular Carcinoma

Qi Wang, Xiangyu Zhang, Hongze Liao, Ying Sun, Li Ding, Yanwei Teng, Wei‐Hong Zhu, Zhirong Zhang, Yourong Duan

Advanced Functional Materials· Volume 28· Issue 14
Publisher page

Abstract

Abstract Multidrug resistance (MDR) is the main obstruction against the chemotherapy for hepatocellular carcinoma. Herein, a biodegradable multifunctional tumor‐targeted core–shell structural nanocarrier (RGD peptide functionalized nanoparticles, RGD‐NPs) is reported for treating MDR hepatocellular carcinoma, which consists of three components: pH‐triggered calcium phosphate shell, long circulation phosphatidylserine‐polyethylene glycol (PS‐PEG) core, and an active targeting ligand RGD peptide. Drug‐resistance inhibitor (verapamil, VER) and chemotherapeutic agent (mitoxantrone, MIT) are separately encapsulated into the outer shell layer and inner core layer to obtain VER and MIT loaded RGD‐NPs (VM‐RGD‐NPs). Due to the shell–core structure, the VER and MIT can release sequentially, thus synergistically weakening the efflux effect to MIT by MDR cells. Also, the calcium phosphate can trigger lysosomal escaping through the varied pH value. Together with the optimized internalization pathway in MDR tumor cells, the increased intracellular effective chemotherapeutic drug concentration can be realized, thus achieving the improved curative effect. In this system, the PEG extends the circulation time in vivo. Also, the peptide RGD distinctly increases the affinity to MDR tumors with respect to nontargeted nanoparticles. As a consequence, VM‐RGD‐NPs exhibit a significant synergistic effect toward the MDR hepatocellular carcinoma, providing a promising therapeutic approach for MDR tumor.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Drug Transport and Resistance Mechanisms · Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Oncogenes and Related Genes Shanghai Cancer Institute Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai 200032 China

Key Laboratory for Advanced Materials and Institute of Fine Chemicals Shanghai Key Laboratory of Functional Materials Chemistry School of Chemistry and Molecular Engineering East China University of Science and Technology Shanghai 200237 P. R. China

Key Laboratory of Drug Targeting and Novel Drug Delivery Systems Ministry of Education West China School of Pharmacy Sichuan University Chengdu Sichuan 610041 China

Funding

National Natural Science Foundation of China

References (66)

Show source-provided references
1. Raza A. · World J. Gastroenterol. · 2008 · 70 · 4115
2. 10.4236/ojrad.2015.5100910.4236/ojrad.2015.51009 ↗
3. 10.4254/wjh.v7.i26.264810.4254/wjh.v7.i26.2648 ↗
4. 10.1002/adma.20170099610.1002/adma.201700996 ↗
5. 10.1002/adma.20160686410.1002/adma.201606864 ↗
6. 10.1002/adfm.20170060510.1002/adfm.201700605 ↗
7. 10.3390/cancers603176910.3390/cancers6031769 ↗
8. 10.1038/nrd198410.1038/nrd1984 ↗
9. 10.1016/j.drup.2014.11.00210.1016/j.drup.2014.11.002 ↗
10. 10.3389/fphar.2013.0002810.3389/fphar.2013.00028 ↗
11. 10.1016/S0344-0338(96)80099-910.1016/S0344-0338(96)80099-9 ↗
12. 10.1146/annurev.med.53.082901.10392910.1146/annurev.med.53.082901.103929 ↗
13. 10.1016/j.ddmec.2004.10.00110.1016/j.ddmec.2004.10.001 ↗
14. 10.1038/nrc70610.1038/nrc706 ↗
15. 10.1016/j.addr.2012.09.02710.1016/j.addr.2012.09.027 ↗
16. Taniguchi K. · Cancer Res. · 1996 · 56 · 4124
17. 10.1159/00013459910.1159/000134599 ↗
18. 10.1093/hmg/5.10.164910.1093/hmg/5.10.1649 ↗
19. 10.1073/pnas.95.26.1566510.1073/pnas.95.26.15665 ↗
20. 10.1002/smll.20160286910.1002/smll.201602869 ↗
21. 10.1002/adfm.20140293010.1002/adfm.201402930 ↗
22. 10.1002/adfm.20147016110.1002/adfm.201470161 ↗
23. 10.1002/adfm.20167015410.1002/adfm.201670154 ↗
24. 10.1007/s11426-015-5490-y10.1007/s11426-015-5490-y ↗
25. 10.1007/s00280-010-1385-y10.1007/s00280-010-1385-y ↗
26. 10.1111/j.1432-1033.1994.tb18748.x10.1111/j.1432-1033.1994.tb18748.x ↗
27. 10.1007/s00270990028710.1007/s002709900287 ↗
28. 10.2165/00023210-200418060-0001010.2165/00023210-200418060-00010 ↗
29. 10.2174/138161282266616061711211110.2174/1381612822666160617112111 ↗
30. Mistry S. K. · Front. Pharmacol. · 2014 · 5 · 159
31. 10.3892/ol.2016.459610.3892/ol.2016.4596 ↗
32. 10.1016/j.febslet.2006.02.02010.1016/j.febslet.2006.02.020 ↗
33. 10.2174/156801104348219710.2174/1568011043482197 ↗
34. 10.1016/j.biomaterials.2011.03.07110.1016/j.biomaterials.2011.03.071 ↗
35. 10.1016/j.jconrel.2009.01.02110.1016/j.jconrel.2009.01.021 ↗
36. 10.1016/j.jconrel.2011.03.01710.1016/j.jconrel.2011.03.017 ↗
37. 10.1002/adfm.20130104510.1002/adfm.201301045 ↗
38. 10.1002/adfm.20110084010.1002/adfm.201100840 ↗
39. 10.1016/j.ijpharm.2011.05.08210.1016/j.ijpharm.2011.05.082 ↗
40. 10.1002/jps.2220010.1002/jps.22200 ↗
41. 10.1016/j.ejps.2009.02.01810.1016/j.ejps.2009.02.018 ↗
42. 10.1016/j.biomaterials.2015.03.05010.1016/j.biomaterials.2015.03.050 ↗
43. 10.1039/c2jm15586a10.1039/c2jm15586a ↗
44. 10.1007/s11051-014-2421-310.1007/s11051-014-2421-3 ↗
45. 10.3109/17435390.2014.91138110.3109/17435390.2014.911381 ↗
46. 10.1039/B917441A10.1039/B917441A ↗
47. 10.1016/j.biomaterials.2012.05.05910.1016/j.biomaterials.2012.05.059 ↗
48. 10.1039/C4RA09902H10.1039/C4RA09902H ↗
49. 10.1016/j.biomaterials.2016.12.03110.1016/j.biomaterials.2016.12.031 ↗
50. Ollivier L. · Blood · 1998 · 91 · 448010.1182/blood.V91.8.2698.2698_2698_2703 ↗
51. 10.1002/cyto.107210.1002/cyto.1072 ↗
52. 10.1007/s00018-003-3336-910.1007/s00018-003-3336-9 ↗
53. Ponte‐Sucr A. · 2009
54. 10.1021/cm040056i10.1021/cm040056i ↗
55. 10.1039/C5TB00912J10.1039/C5TB00912J ↗
56. 10.1016/j.jconrel.2011.10.02010.1016/j.jconrel.2011.10.020 ↗
57. 10.1126/science.609326310.1126/science.6093263 ↗
58. 10.1016/0092-8674(86)90362-410.1016/0092-8674(86)90362-4 ↗
59. 10.1158/2159-8290.CD-13-061110.1158/2159-8290.CD-13-0611 ↗
60. 10.1158/0008-5472.CAN-09-148210.1158/0008-5472.CAN-09-1482 ↗
61. 10.1021/acsnano.5b0686010.1021/acsnano.5b06860 ↗
62. 10.5487/TR.2013.29.1.00110.5487/TR.2013.29.1.001 ↗
63. 10.1016/j.ajpath.2012.09.02510.1016/j.ajpath.2012.09.025 ↗
64. 10.1016/j.jpba.2009.09.02710.1016/j.jpba.2009.09.027 ↗
65. 10.1016/j.jchromb.2010.06.01610.1016/j.jchromb.2010.06.016 ↗
66. 10.1016/j.jbbm.2007.09.00910.1016/j.jbbm.2007.09.009 ↗